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Amyloidosis is a disease of constitutive protein misfolding resulting in extracellular 
deposition of pathological, insoluble, β-sheet fibrillar bundles that destroy the structure 
and function of affected organs and tissues. Cardiac infiltration traditionally implies a 
very poor prognosis1-4. The major systemic amyloidoses associated with cardiac 
deposition5, 6 are primary light chain amyloidosis (AL amyloidosis) arising from 
abnormal immunoglobulin light chain deposition; wild-type amyloidosis (ATTRwt) 
resulting from hepatic-derived wild type transthyretin accumulation; and hereditary or 
familial amyloidosis (ATTRv) due to deposition of mutant transthyretin proteins. The 
main constituent fibril protein in tissue deposits determines the amyloid subtype. The 
importance of correct subtype classification cannot be overstated, due to significant 
differences in the treatment and prognosis of the various amyloid subtypes.  
Immunohistochemistry (IHC) on tissue samples has been recommended to assist in 
diagnosis, however it is largely unreliable outside of highly specialised centres such as 
the United Kingdom National Amyloid Centre (NAC)7-11. 
Laser microdissection and tandem mass spectrometry (LMD-MS)-based proteomic 
analysis has been demonstrated to have 98% accuracy for subtype classification 
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compared with 42% for IHC performed on the same samples12.  In an Australian series 
utilising LMD-MS on 138 biopsies from 35 organ sites (including 24 cardiac biopsies) 
the amyloid subtype was identified in 121 out of 131 cases (92%)11.  Few studies have 
reported patient outcomes on the basis of direct fibril assessment from cardiac samples 
and there is limited data on the Australian experience with cardiac amyloidosis.   
Given the poor reliability of IHC determination of amyloid subtype, we aimed to 
definitively characterise the amyloid subtype by mass spectrometry in an Australian 
cohort of patients with cardiac amyloidosis. 
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Methods  
Study Design 
St Vincents Hospital, Sydney is the state-wide referral centre for cardiac 
transplantation in New South Wales and South Australia and provides a diagnostic 
endomyocardial biopsy service. Patients with histologically confirmed amyloid 
deposition in cardiac tissue samples were identified from the Anatomical Pathology 
database of St Vincent’s Hospital (SVH), Sydney between 1992 and 2011. This 
included endomyocardial biopsies collected at SVH and samples referred for review 
by Royal Adelaide Hospital (RAH). Amyloid deposition was confirmed by positive 
Congo red staining and polarisation microscopy.  IHC was not routinely performed 
due to poor reliability and poor positive predictive value.  Genetic mutation analysis 
was performed on selected patients. 
 
Clinical data was collected retrospectively from the medical records at SVH and RAH, 
and from community medical providers. For the purposes of this study, amyloid 
diagnosis was considered to be at the time of endomyocardial biopsy. Demographic 
data, symptoms, co-morbidities and organ involvement at the time of diagnosis were 
noted, as well as available treatment details.  
 
Amyloid subtype analysis by LMD-MS was performed at the Clinical Proteomics 
Laboratory, Mayo Clinic, Rochester as previously described12, on diagnostic, formalin-
fixed, paraffin-embedded endomyocardial tissue blocks. Briefly, paraffin sections were 
stained with Congo red, and amyloid deposits identified under fluorescent light were 
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microdissected using LMD. Microdissected fragments were digested into tryptic 
peptides and analysed by liquid chromatography electrospray tandem mass 
spectrometry (MS). MS raw data was queried using different algorithms to assign 
peptide and protein probability scores. 
 
Survival was measured from the date of endomyocardial biopsy. Follow-up was closed 
in November 2013 with attempts made to contact all patients not reviewed within the 
prior 6 months, and patient survival censored at the last known date of contact. 
 
The study was approved by the SVH Human Research and Ethics Committee (Approval 
Number H10/205), and the RAH Research Ethics Committee (Approval Number 
111205).  Informed consent was obtained from all patients alive at the time of study 
enrolment.  An ethics application was made to the Australian Institute of Health and 
Welfare to obtain survival data from the National Death Index for patients biopsied prior 
to 2010.  
 
Baseline Assessment 
Assessment of organ involvement, symptoms, cardiac staging and plasma cell clone. 
Organ involvement was noted for any patient with amyloid deposition on organ biopsy 
or on the basis of the following definitions. Renal involvement was defined as 24-hour 
urine protein excretion ≥0.5g/day or elevated creatinine (≥90umol/L in females, and 
≥120umol/L in males).  Hepatic involvement was defined as a serum alkaline 
phosphatase value >1.5 times the upper limit of the institutional reference range 
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(>150U/L)13. Peripheral nerve involvement was defined as otherwise unexplained 
symptoms of peripheral neuropathy. Upper gastrointestinal (GI) symptoms included 
dysphagia, reflux or peptic ulcer disease, nausea, vomiting, epigastric discomfort, or 
symptoms prompting endoscopic investigation (gastroscopy). Lower GI symptoms 
included constipation, diarrhoea, abdominal bloating, or symptoms prompting 
endoscopic investigation (colonoscopy).  
 
Assessment of cardiac disease utilised troponin assays and from March 2009, NT-
proBNP.  The institutional reference ranges for NT-proBNP, troponin I and troponin T 
changed throughout the study period and values are reported as elevated above reference 
range. Troponin T results have been pooled irrespective of the use of standard or high 
sensitivity assay. Electrocardiogram (ECG) low voltage criteria14 were defined as 
presence of QRS voltage amplitude ≤0.5mV in limb leads.  Cardiac arrhythmia included 
self-reported or documented history of any arrhythmia or pacemaker insertion prior to 
diagnosis. 
 
Evaluation for Plasma Cell Clone 
Identification of monoclonal proteins in serum and urine were based on electrophoresis 
(EPG) +/- immunofixation electrophoresis (IFE). Free light chain (FLC) measurements 
were available for patients diagnosed after 2004. The institutional reference range FLC 
ratio is 0.26-1.65mg/L, kappa light chain 3.3-19.4mg/L, and lambda light chain 5.7-
26.3mg/L. Bone marrow biopsy was reported where available, with 10% plasma cells 
infiltration used as the threshold of significant plasma cell burden (in keeping with 
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Statistical analyses were conducted with IBM SPSS Statistics version 22.  Summary 
statistics are expressed as medians or frequencies (percentages). Categorical variables 
were compared with the Pearson’s chi-squared or Fisher exact test. Independent samples 
t-test was used to compare normally distributed continuous variables, and a Mann-
Whitney U test was utilised for non-parametric comparisons, between ATTRwt and AL 
groups. Values of P ≤ 0.05 were considered significant. Overall survival was estimated 
using Kaplan-Meier survival curves and compared by log-rank test. Selected variables 
potentially impacting survival of AL patients were tested in univariate and multivariate 
models. A series of univariate cox regressions were performed to assess the impact on 
survival for each variable and any variables reaching significance were analysed 




Fifty-eight patients with amyloid deposition present on cardiac biopsy were identified 
(see Study Flowchart, Figure 1). Eleven patients were excluded for the following 
reasons: biopsy was not performed at diagnosis (e.g. autopsy biopsy) (5), patients 
referred from overseas and uncontactable (2), unable to be contacted (1), declined 
participation (1) and inadequate tissue and clinical information (1)  Of the 47 patients 
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who were eligible for inclusion, 39 patients undergoing subtyping by laser 
microdissection and tandem mass spectrometry (LMD-MS) while 8 were subtyped on 
the basis of clinical findings and other investigations.  Survival analysis was performed 
on the 32 AL amyloid patients and 12 ATTwt patients. 
 
Laser Microdissection and Tandem Mass Spectrometry (LMD-MS) Subtype Analysis 
Of the 47 patients, only 41 had endomyocardial biopsy tissue blocks available for LMD-
MS, and two blocks were insufficient for analysis. Hence 39 of 47 (83%) patients were 
subtyped by LMD-MS: 11 as ATTRwt; 27 as AL (19 lambda and 8 kappa); and 1 as 
heavy chain (AH) amyloid. Three patients with complex presentations were clarified by 
the LMD-MS results (1 IgG1 heavy chain amyloid, 2 ATTRwt).  The two ATTRv 
patients did not have sufficient tissue available for LMD-MS, and none of the patients 
investigated by LMD-MS were reported to have a dominant amyloid protein suggestive 
of hereditary amyloidosis. 
 
Demographics, and Clinical Characteristics  
The demographic data and clinical characteristics of the 47 patients (SVH 34; RAH 13) 
at diagnosis were compared according to subtype (Table 1).  In addition to the 39 
patients with LMD-MS confirmed subtype, the remaining 8 patients eligible for 
inclusion (ATTRv 2; ATTRwt 1; AL 5) were subtyped on the basis of clinical findings 
and other investigations and included in the analysis (see Figure 1). 
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Primary AL was diagnosed in 68% (n=32), ATTRwt in 26% (n=12), ATTRv in 4% 
(n=2), and AH in 2% (n=1) of the cohort. In comparison to AL/AH amyloid patients, 
ATTRwt patients were older (ATTRwt, 76y (69-88y); AL/AH, 60y (41-83y); P<0.01), 
and the majority of ATTRwt patients were male (ATTRwt, males, n=11, 92%; AL, 
males, n=15, 45%; P<0.001).  
 
Median symptom duration prior to diagnosis ranged from 10-34 months.  The presenting 
symptoms did not differ significantly between the ATTRwt and AL/AH amyloid 
subtypes.  Multi-organ involvement, particularly renal involvement, was frequent in AL 
patients, occurring in 61% of patients.  Other organ involvement was confirmed on 
tissue biopsy in AL patients: liver (1), pleural (1), pulmonary (1), muscle (1), and 
gastrointestinal (3). As expected, ATTRwt rarely involved other organs. A history of 
carpal tunnel syndrome or surgery was common across all subtypes. 
 
Severe congestive cardiac failure symptoms (NYHA III or IV) were present at time of 
amyloid diagnosis in 39% of AL/AH patients and 27% of ATTRwt patients (see Table 
1). A significantly higher number of ATTRwt patients had a history of arrhythmia or 
pacemaker insertion, compared to AL patients (ATTRwt, n=9, 75%; AL, n=9, 31%; 
P=0.016) and mean interventricular septal (IVS) width was also significantly higher in 
ATTRwt amyloid patients (ATTRwt 22mm; AL 15mm; P=0.005). Other cardiac 
parameters were not significantly different.  All patients with ATTRwt (n=5) and AL 
(n=12) with available NT-proBNP results, were above the institutional reference range.  
 
This article is protected by copyright. All rights reserved.
Genetic Studies 
Two male patients, aged 49 and 55, were diagnosed with hereditary ATTR on the basis 
of clinical characteristics and heterozygosity for the transthyretin Thr60Ala 
(p.TTRT60A) mutation proven on sequencing.  Both presented with symptomatic 
cardiac involvement, one had peripheral neuropathy and GI involvement at diagnosis, 
and the other patient went on to develop these manifestations.  Neither patient reported 
a known family history of amyloidosis.  
 
Evaluation for plasma cell clone 
None of the ATTRwt or ATTRv patients with available records had documentation of 
a monoclonal gammopathy in urine or serum or an abnormal FLC ratio. Of the 32 
patients with AL, 25% had a kappa restriction with median involved serum kappa light 
chains of 902mg/L (range 238-4470), and 75% demonstrated a lambda restriction with 
median involved serum lambda light chains of 299mg/L (range 79-2524). Just over one 
third of AL patients with bone marrow studies available had greater than 10% plasma 
cells on aspirate. No patient had a recorded pre-existing diagnosis of symptomatic 




For the 23 AL/AH patients with initial treatment recorded, the majority (n=15, 65%) 
received intravenous or oral melphalan plus corticosteroids, 4 (17%) received 
thalidomide or bortezomib containing regimens, 2 (9%) received vincristine, adriamycin 
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and dexamethasone combination chemotherapy, and 2 (9%) patients received 
colchicine.  As a referral rather treating centre, adequate information was not available 
to assess haematological or organ response in the majority of patients studied.  During 
the time period evaluated in this study, cardiac AL/AH amyloidosis was considered a 
contraindication to cardiac transplantation and in most circumstances, autologous stem 
cell transplantation was also contraindicated. 
 
After a median follow-up of 63 (0.2-90) months, 7 patients remained alive (4 [33%] 
with ATTRwt and 3 [9%] with AL. Patients with AL had significantly inferior overall 
survival (OS) than the ATTRwt amyloid group (median survival 3.5 months vs. 37 
months, p=0.007) (Figure 2).  OS for AL was 37% at 1 year and 15% at 5 years; 
compared to 100% at 1 year and 44% at 5 years for ATTRwt amyloid. The patient with 
AH amyloid (not included in the AL survival curve) survived for 41 months.  Of the 
two hereditary amyloid patients, one died after 44 months while awaiting combined 
cardiac-liver transplant and the other died after 12 months from severe autonomic, 
cardiac and gastrointestinal involvement precluding transplant. 
 
The small dataset for the ATTRwt and ATTRv cohorts precluded further assessment of 
the impact of baseline characteristics on survival outcome. However, a variety of 
characteristics were analysed for the AL cohort (Table 2).  Univariate cox regressions 
suggested that renal impairment (HR 2.48, P=0.05), NYHA class III-IV symptoms (HR 
5.02, P=0.002), year of diagnosis prior to 2000 (HR 2.76, P=0.02), plasma cells ≥10% 
on bone marrow biopsy (HR=3.88, P=0.02), and raised troponin I >0.1ug/L or troponin 
This article is protected by copyright. All rights reserved.
T >77ng/L (HR=4.72, P=0.02) were all associated with a significantly poorer survival. 
On multivariate cox regression NYHA class III-IV (HR=5.21, CI=1.21-22.49, P=0.03) 
and bone marrow plasma cells ≥10% (HR=3.26, CI=0.97-10.91, P=0.05) at diagnosis 
were the only independent variables significantly associated with worse survival.  
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Discussion  
This study describes the characteristics and very poor survival of a cohort of patients 
with biopsy proven cardiac amyloidosis. To our knowledge, this is the largest Australian 
study characterising patients with cardiac amyloidosis. This study was performed in the 
era before bone scintigraphy was commonly used as part of the diagnostic approach for 
assessing suspected cardiac amyloid. The majority of patients (83%) were categorised 
on the basis of definitive amyloid subtype based on LMD-MS performed on cardiac 
tissue.  
 As expected, AL was the dominant cardiac subytpe identified in 68% of the cohort.  
Prognostic systems used for cardiac AL amyloidosis incorporate the cardiac biomarkers 
Troponin T or I and ProBNP16, 17.  Assessment of available cardiac biomarkers in our 
cohort demonstrated a significant proportion of patients with poor prognosis disease.  
Based on the 2004 Mayo Staging System18, 56% of AL patients tested (n=18) would be 
at least stage II, and of those, 7 of the 9 (78%) with proBNP and troponin assessment 
available were Stage III.  This correlates with a median survival of 10.5-11.1 months 
and 3.5 months respectively which is in keeping with the median overall survival of 3.5 
months in our cohort18.  The updated Mayo Staging System by Kumar et al16 also 
incorporates evaluation of the plasma cell clone utilising the Freelite FLC assay and 
demonstrated that a difference in FLCs (dFLC = involved FLC – uninvolved FLC), 
above thresholds of λ>182mg/L or κ>294mg/L, has been correlated with significantly 
reduced survival19.  Our cohort demonstrated considerably higher median dFLCs of 
λ=297mg/L and κ= 895mg/L, highlighting that the poor prognosis of our cohort was not 
unexpected.  In our cohort, only NHYA class III-IV and plasma cells ≥10% were 
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demonstrated to be significant independent predictors of inferior survival, emphasising 
that prognostic outcome is ultimately a function of both cardiac organ involvement and 
plasma cell activity/burden. 
A significant proportion of the AL cohort were diagnosed prior to availability of highly 
effective immunomodulatory chemotherapies and were treated palliatively.  In addition 
to the advent of immunomodulatory therapy, there is an emerging role for cardiac 
transplantation in advanced AL amyloidosis.  An approach of induction chemotherapy, 
cardiac transplantation and subsequent autologous stem cell transplantation in patients 
with advanced AL amyloidosis and limited extracardiac disease has been demonstrated 
to be feasible and associated with impressive survival rates given the historically poor 
prognosis of these patients20-24 and is currently under investigation in an Australian 
Phase II study24. 
 
The ATTRwt subtype was found to be relatively common comprising 26% of cardiac 
amyloid diagnoses, while underlying genetic mutations contributing to cardiac 
amyloidosis were rare (4%). The two patients with hereditary amyloidosis were 
diagnosed with familial amyloid polyneuropathy (FAP) and the clinical picture was 
typical of the cardiac predominant phenotype of the TTR T60A mutation2, 25. The rate 
of ATTRwt was unexpectedly high compared to other studies of cardiac amyloidosis 
where incidence of ATTRwt was reported to be 4-6%3, 6. The high incidence of ATTRwt 
in our cohort likely reflects the predominant cardiac presentation of ATTRwt, and the 
fact that our cohort were identified from cardiac biopsy samples.  A recent study from 
the National Amyloidosis Centre (NAC) of the United Kingdom suggested ATTRwt 
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was clinically underrecognised prior to 200926.  The development of new non-invasive 
testing methods such as cardiac magnetic resonance imaging (cMRI) and bone 
scintigraphy were suggested to account for an increased cumulative incidence of 
ATTRwt diagnoses (25%) between 2015-2019 compared to 3% between 1987-2009.  
Consistent with previous studies, our patients with ATTRwt cardiac amyloidosis were 
predominantly male, older, had increased frequency of conduction abnormalities and 
did not have evidence of renal involvement27.  However, these characteristics cannot be 
used to definitely subtype cardiac amyloidosis as there is significant overlap between 
ATTRwt and AL.   
The advent of bone scintigraphy in recent years, enables a diagnosis of ATTRwt cardiac 
amyloid to be made in the absence of a tissue biopsy, but only in cases where there is 
no detectable plasma cell clone (i.e. no monoclonal protein on serum or urine EPG or 
immunofixation, and normal serum free light chain ratio).  It is 99% sensitive and 86% 
specific for ATTRwt amyloid, however a proportion of patients with AL amyloid will 
have cardiac uptake on bone scintigraphy28, 29.   Given that patients diagnosed with 
ATTRwt are usually older and the incidence of monoclonal gammopathy rises with 
age30; concurrent ATTRwt with evidence of plasma cell clonal gammopathy is not 
uncommon.  In the instance of cardiac uptake on bone scintigraphy and a detectable 
plasma cell clone, accurate determination of amyloid subtype is essential to determine 
therapy and prognosis and can only be ascertained by cardiac biopsy and direct amyloid 
fibril assessment.    
LMD-MS 12 is a diagnostic assay reported to be highly accurate for assessing the specific 
nature of the amyloid fibril protein.  A number of reports have highlighted the potential 
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for amyloid subtype misdiagnosis using clinical phenotype or immunohistochemistry, 
without direct fibril assessment7-9, 31. Investigators from the NAC reported that of 350 
patients thought to have AL, 10% were found to have amyloidogenic mutations and 
24% of those patients were noted to have a concurrent low grade monoclonal 
gammopathy31. The limitations of relying on IHC for amyloid subtyping have been 
previously highlighted in an Australian cohort where IHC and LMD-MS were 
performed in 88 cases; in 49 cases IHC was non-diagnostic or uninterpretable, and in 5 
of 39 cases the subtype was inaccurately characterised on the basis of IHC11.  A further 
challenge to accurate diagnosis in the Australian setting is the lack of access to LMD-
MS, as there is no current accredited local diagnostic laboratory and the cost of testing 
in overseas centres is unfunded. In our study, LMD-MS resulted in a definitive subtype 
for 39 patients and clarified the diagnosis in 3 complex patients.  While misdiagnosis 
appears to only occur in a small percentage of patients, and has probably been reduced 
using new diagnostic algorithms (see figure 3) incorporating bone scintigraphy, 
substantial differences in prognosis and treatment highlight the importance of an 
accurate diagnosis3, 6, 32, 33.   
The limitations of this study arise from the small number of participants, and the 
retrospective nature of the data.  The study context also deserves consideration as St 
Vincent’s hospital is a quaternary referral centre for cardiac transplantation, with 
expertise in endomyocardial biopsy. This referral bias may have impacted the 
presentation of amyloid subtypes in the study. However, given the rarity of this disease, 
these limitations are offset by the opportunity to gain insights from a cohort of patients 
with long follow up and biopsy-proven cardiac amyloidosis. It would be valuable to 
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confirm these findings with data from large prospective studies and registries in light of 
novel therapies for AL and ATTRwt. 
 
Conclusion 
This study fills an important gap in the epidemiology of cardiac amyloid in 
Australia and reports survival outcomes on the basis of highly accurate amyloid fibril 
assessment. AL amyloid was associated with very poor survival, predicted on the basis 
cardiac failure symptoms and bone marrow plasmacytosis. TTR amyloidosis was more 
common than previously described, affecting almost a third of patients, however the 
majority of these patients could not be offered any specific therapy at the time, and over 
half of patients died within 5 years.  There are a number of new treatments now available 
or undergoing investigation including TTR stabilisers (diflunisal, tafamidis) and TTR 
synthesis inhibitors (patisiran and inotersen)33, although none are currently funded in 
Australia.  Despite the increasing emergence of diagnostic strategies (see Figure 3) that 
may abrogate the need for tissue biopsy in some cases, LD-MS plays an important role 
in complex cases.  The establishment of the Australian Amyloidosis Network 
facilitating collection and publication of data in this rare patient group will hopefully 
lead to earlier and more accurate diagnosis and optimised management pathways.  
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Table 1.  Baseline clinical characteristics 
Table 2. Cox regression survival analysis of diagnostic variables in AL 
Figure 1.  Study flow chart 
Figure 2.  Kaplan-Meier survival curve of ATTRwt vs. AL showing significant poorer 
survival of AL patients 
Figure 3.  Diagnostic approach to suspected cardiac amyloidosis 
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Male sex, n (%) 11 (92) 15 (46) 2(100) 0.006
Age at diagnosis, y - median (range), 76 (69-88) 60 (41-83) 52 (49-55) < 0.001
Symptom duration, m - median (range), (n=9/26/2) 18(4-84) 10 (1-48) 34 (7-60) 0.093
Symptoms, n (%) (n=9/26/2)
Dyspnoea on exertion 8 (89) 25 (96) 2 (100) 0.454
Dyspnoea at rest 2 (22) 7 (27) 0 1.000
Syncope 1 (11) 4 (15) 1 (50) 1.000
Dizziness 0 7 (27) 1 (50) 0.153
Palpitations 1 (11) 5 (19) 1 (50) 1.000
Peripheral oedema 6 (67) 17 (65) 1 (50) 1.000
Effusions or ascites 3 (33) 10 (39) 0 1.000
Upper GI symptoms 5 (56) 16 (62) 0 1.000
Lower GI symptoms 0 8 (31) 1 (50) 0.081
Weight loss 2 (22) 14 (54) 1 (50) 0.135
Organ involvement, n (%)
Renal (n=5/23/2) 0 14 (61) 0 0.041
Liver (n=7/25/1) 2 (29) 8 (32) 0 1.000
Carpal tunnel symptoms/surgery (n=12/29/2) 5 (42) 10 (35) 1 (50) 0.730
Gastrointestinal (on biopsy) 0 3 1
Peripheral nerve (symptomatic) 0 4 1
Macroglossia (symptomatic) 0 3 0
Other (see text) 0 3 0
>2 organs involvment (including cardiac) (n=8/28/2) 1 (13) 12 (43) 1 (50) 0.213
Baseline laboratory values
Monoclonal protein in serum, g/L, n (%) (n=9/26/2) 0 14 (54) 0 0.005
Monoclonal protein in urine, g/L, n (%) (n= 8/26/2) 0 17 (65) 0 0.001
Abnormal free light chain ratio, n (%) (n= 6/19/1) 0 18 (95) 0 <0.001
Median κ light chain, mg/L (range) (n=6/18/1) 17 (8-25) 22 (5-4470) 15 0.626
Median λ light chain, mg/L (range) (n=6/19/1) 21(11-44) 209 (7-2524) 19 0.043
Median light chain difference, mg/L (range) (n=17) 6 (1-23) 455 (68-4462) 4 <0.001
Plasma cells >10% on bone marrow aspirate, n (%) (n=2/20/2) 0 7 (35) 0 1.000
Median BM plasma cell percentage, % (range) (n=1/16/1) 1 7 (2-50) 2 0.118
Proteinuria >0.5g/d, n % (n=5/23/2) 0 13 (57) 0 0.044
Median urine protein, g/24hr (range) (n=3/18/1) 0.19 (0.18-0.32) 1.26 (0.07-4.98) 0.17 0.307
Renal impairment, n (%), (n=9/27/2) 1(11) 13 (48) 0 0.062
Cardiac Parameters
NYHA Class I-II, n (%) (n=11/28/2) 8 (73) 17 (61) 2 (100) 0.713
Prior cardiac arrhthymia or pacemaker insertion (n=12/29/2)  9 (75) 9 (31) 1 (50) 0.016
ECG - low voltage, n (%) (n=8/22/2) 4 (50) 17 (77) 0 0.195
EF < 50% - systolic dysfunction, n (%) (n=9/26/1) 4 (44) 6 (23) 0 0.393
Median interventricular septal thickness, mm (range) (n=7/25/2) 22.0 (12-24) 15.0 (10-21) 16.5 (15-18) 0.005
Raised NT-proBNP above reference range, n (%) (n=5/12/1) 5 (100) 12 (100) 1 (100)
NT-proBNP, ng/L (range) (n=5/12/1) 1931 (855-8810) 4781 (415-34340) 1350 0.506
Raised troponin I/T above reference range, n (%) (n=4/17/1) 3 (75) 11 (65) 0 1.000
Median troponin I, ug/L (range) (n=0/6/0) - 0.225 (0.030-0.430) -
Median troponin T, ng/L (range) (n=4/10/1) 67 (30-82) 64 (10-486) 10 1.000
‡ P value refers to comparison between ATTRwt and AL/AH groups only.
Characteristic (n= evaluable patients in each group†) ATTRwt (n=12) AL/AH (n=33) ATTRv 
(n=2)
P value‡
†Sample size as stated for each subtype unless otherwise indicated. 










Hazard ratio (95% CI)
P-
value Hazard ratio (95% CI) P-value
Age >= 60 yrs 1.67 (0.77-3.66) 0.2
Male 0.69 (0.33-1.44) 0.3
Symptoms prior to diagnosis >= 12 mth 1.29 (0.57-2.94) 0.5
Organs involvement >=3 0.60 (0.26-1.35) 0.2




Year of diagnosis prior to 2000 2.76 (1.22-6.24) 0.02
NYHA severity stage III/IV 5.02 (1.78-14.13) 0.002 5.21 (1.21 – 22.49) 0.03
Interventricular septal width >=16mm 0.94 (0.39-2.28) 0.9
Systolic dysfunction EF < 50% 0.98 (0.36-2.70) 0.97
Troponin I >=0.1ug/L or T >=77ng/L 4.72 (1.33-16.69) 0.02
NT-proBNP >=2736ng/L 1.97 (0.49-7.86) 0.3
Kappa light chain restriction 1.51 (0.63-3.62) 0.4
Lambda light chain restriction 0.66 (0.28-1.60) 0.4
iFLC κ >=900mg/L or λ >=300mg/L 2.01 (0.71-5.72) 0.2
dFLC >=180mg/L 2.27(0.50-10.27) 0.3
dFLC >=450mg/L 3.11(0.91-10.60) 0.07
Plasma cells on marrow aspirate >=10% 3.88 (1.28-11.75) 0.02 3.26 (0.97-10.91) 0.05
Independent Variable
Univariate analysis Multivariate analysis
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